WELLESLEY HILLS, Mass., Dec. 5 /PRNewswire-FirstCall/ -- MacroChem’s , (www.macrochem.com) President and CEO, Robert DeLuccia, will present at the upcoming Equities Magazine Winter Discovery Day Conference XV at the Princeton Club in New York City on December 7, 2007. Mr. DeLuccia is scheduled to present at 11:30 AM EST.
The Equities Corporate Conference is an all day event featuring special presentations from emerging public company CEOs from a wide range of sectors. The conference provides an opportunity for promising emerging growth companies to connect with the investment community. Interested parties can access a live audio webcast of the Company’s presentation, through a link at www.equitiesmagazine.com. The presentation will be available for 90 days.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, www.macrochem.com.
About Equities Magazine
EQUITIES magazine is focused on bringing together corporate executives and corporate and institutional investment professionals who closely follow and invest in mid cap and small cap growth companies. Their corporate conferences now celebrate 25 years of bridging the gap between emerging public companies and the investment community.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, www.macrochem.com.
bpatriacca@macrochem.comcberni@investorrelationsgroup.comjtriunfo@investorrelationsgroup.combdouglass@investorrelationsgroup.commheller@investorrelationsgroup.com
CONTACT: Bernard Patriacca, VP/CFO of MacroChem, +1-781-489-7310,
bpatriacca@macrochem.com; or Investor Relations, Christine Berni,
cberni@investorrelationsgroup.com, or Joseph Triunfo,
jtriunfo@investorrelationsgroup.com, +1-212-825-3210, or Media, Bill
Douglass, bdouglass@investorrelationsgroup.com, or Michaela Heller,
mheller@investorrelationsgroup.com, +1-212-825-3210, all of The Investor
Relations Group for MacroChem Corporation
Web site: http://www.macrochem.com/
http://www.equitiesmagazine.com/
